Know Cancer

forgot password

Pilot Trial of CRLX101 in the Treatment of Patients With Advanced HER-2 Negative Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma

18 Years
Open (Enrolling)
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer

Thank you

Trial Information

Pilot Trial of CRLX101 in the Treatment of Patients With Advanced HER-2 Negative Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma


I. To evaluate pre- and post-treatment biopsies to assess CRLX101 (cyclodextrin-based
polymer-camptothecin CRLX101) nanoparticle and 20(S)-Camptothecin (CPT) uptake in tumor and
normal tissue.


I. To evaluate the safety and toxicity of CRLX101 in this patient population. II. To examine
the antitumor efficacy of CRLX101 in advanced gastric/gastroesophageal junction
(GEJ)/esophageal squamous or adenocarcinoma including clinical benefit rate (complete
response [CR] + partial response [PR] + stable disease [SD]) at 4 months and overall


Patients receive cyclodextrin-based polymer-camptothecin CRLX101 intravenously (IV) over 60
minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of
disease progression or unacceptable toxicity.

Patients achieving stable disease or better, may receive treatment for an additional 6

After completion of study treatment, patients are followed up monthly.

Inclusion Criteria:

- Patients must have histologically confirmed advanced or metastatic squamous
adenocarcinoma of the esophagus, GEJ, and stomach

- Patients must have primary tumor and adjacent normal tissue accessible via endoscopic

- Patients must have received at least one prior chemotherapy regimen for their
unresectable or metastatic disease, not including treatment administered in the
adjuvant and/or neoadjuvant setting for curative intent

- Patients must have measurable or evaluable disease

- Absolute neutrophil count >= 1500 cells/uL

- Platelets >= 100,000 cells/uL

- Total bilirubin =< 1.5 times the upper limit of normal (ULN)

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN

- AST/ALT =< 5 x ULN if liver metastasis is present

- Serum creatinine =< 1.5 mg/dL or a measured creatinine clearance >= 50 mL/min

- Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x ULN

- Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

- Subjects with a life expectancy >= 12 weeks

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control or abstinence) prior to study entry and
for six months following duration of study participation; should a woman become
pregnant or suspect that she is pregnant while participating on the trial, she should
inform her treating physician immediately and be discontinued on study; subjects
should be instructed to notify the investigator if it is determined after completion
of the study that they became pregnant during the treatment phase of the study; the
anticipated date or birth or termination of the pregnancy should be provided at the
time of the initial report; whenever possible, a pregnancy should be followed to
term, any premature terminations reported, and the status of the mother and the child
should be reported to the study monitor after delivery; if the outcome of the
pregnancy meets any severe adverse events (SAE) classification criterion, the
investigator must follow the procedures for reporting SAEs; any neonatal death
occurring =< 30 days after birth must also be reported as a SAE

- Subjects must have an electrocardiogram without evidence of clinically significant
conduction abnormalities or active ischemia as determined by the investigator and an
acceptable QTc interval

- All subjects must have the ability to understand and the willingness to sign a
written informed consent

- Subjects must not have received prior chemotherapy or radiation within < 4 weeks
prior to first dose of study drug

- Subjects may be entered if they have received prior radiation therapy involving =<
30% of the bone marrow; any prior radiation therapy must have been administered >= 4
weeks prior to first dose of study drug and the subject must be recovered from the
acute toxic effects of the treatment prior to first dose of study drug (defined as a
return to baseline or a severity of =< grade 1)

- Subjects may be enrolled with a history of treated brain metastases that are
clinically stable for >= 4 weeks prior to the first dose of study drug; subjects may
not be currently receiving dexamethasone

Exclusion Criteria:

- Patients with adenocarcinoma histology and documented HER2 overexpression

- Female subjects who are pregnant or nursing

- Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to first dose of study drug or those who have not
had adverse events return to baseline severity level or a severity of grade 1 due to
agents administered more than 4 weeks prior to first dose of study drug

- Subjects with a history of congestive heart failure (CHF) requiring medical therapy

- Subjects with serum amylase or lipase > 1.5 ULN

- Subjects with previous high dose chemotherapy with autologous stem cell rescue bone
marrow transplantation

- History of organ or allogeneic bone marrow transplant

- Use of any investigational agent or device within 4 weeks prior to first dose of
study drug

- Metastatic disease to the central nervous system (CNS) requiring treatment or
radiation therapy

- Subjects with known untreated brain metastases or treated brain metastases that have
not been stable >= 4 weeks prior to first dose of study drug

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection (including human immunodeficiency virus [HIV] not stable on antiretroviral
therapy), symptomatic congestive heart failure, hypertension, unstable angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements, as determined by the investigator

- History of prior malignancy not cured by excision; patients with non-melanoma skin
cancer or carcinoma in situ of the cervix are not excluded, but patients with other
prior malignancies must have had at least 2-year disease free interval

- Concurrent therapeutic anticoagulation: PTT less than or equal to 1.5 x ULN or low
dose aspirin and low-weight heparin only are allowed; Coumadin will be allowed on a
case by case basis if use is chronic and approved by the study medical monitors

- Any prior cancer treatment with a topoisomerase I inhibitor

- Any major surgery =< 4 week prior to first dose of study drug

- Concurrent use of filgrastim (G-CSF) or growth factors at the time of initiation of
study drug

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to CRLX101 and camptothecins

- Subjects with marked baseline prolongation of QT/QTc interval (for females QTc
interval >= 470 msec and for males QTc interval >= 450 msec)

- Subjects, who in the opinion of the investigator, may not be able to comply with the
safety monitoring requirements of the study

Type of Study:


Study Design:

Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Change in CRLX101 uptake in tumor and nearby normal tissue

Outcome Description:

The effect size is the mean difference divided by the standard deviation of the difference.

Outcome Time Frame:

Baseline and day 8

Safety Issue:


Principal Investigator

Joseph Chao

Investigator Role:

Principal Investigator

Investigator Affiliation:

City of Hope Medical Center


United States: Federal Government

Study ID:




Start Date:

November 2012

Completion Date:

Related Keywords:

  • Adenocarcinoma of the Esophagus
  • Adenocarcinoma of the Gastroesophageal Junction
  • Diffuse Adenocarcinoma of the Stomach
  • Intestinal Adenocarcinoma of the Stomach
  • Mixed Adenocarcinoma of the Stomach
  • Recurrent Esophageal Cancer
  • Recurrent Gastric Cancer
  • Squamous Cell Carcinoma of the Esophagus
  • Stage IIIB Esophageal Cancer
  • Stage IIIB Gastric Cancer
  • Stage IIIC Esophageal Cancer
  • Stage IIIC Gastric Cancer
  • Stage IV Esophageal Cancer
  • Stage IV Gastric Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Esophageal Diseases
  • Esophageal Neoplasms
  • Stomach Neoplasms



City of Hope Medical Center Duarte, California  91010